The Globe and Mail reports in its Thursday edition that Ventum Capital analyst Rob Goff continues to rate Well Health Technologies "buy." The Globe's David Leeder writes in the Eye On Equities column that Mr. Goff gave his share target a 40-cent trim to $7.60. Analysts on average target the shares at $8.18. Mr. Goff says in a note: "Recognizing current headwinds, we look for significant outperformance with the completion of monetizations and continued outperformance across core assets through organic and acquisition-driven gains. Organic growth and appreciating ROIC levels across the core portfolio look to emerge with monetizations of Wisp and Circle. Our bullish outlook for clinic consolidation and subsequent organic growth looks for Well Health to build on its impressive track record empowered by scale and portfolio advantages that allow it to shape-shift clinic economics. The current 'Buy in Canada' focus should lead to tangible wins over the NTM [next 12 months] with the pipeline of 70-plus put at a value of $300-million to $500-million in what we estimate would be $60-million to $80-million of annual revenues." The Globe reported on Jan. 30 that Mr. Goff had rated Well Health "buy." It was then worth $6.22.